Oliver Bandmann
Overview
Explore the profile of Oliver Bandmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
2830
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arena G, Landoulsi Z, Grossmann D, Payne T, Vitali A, Delcambre S, et al.
Ann Neurol
. 2024 May;
96(1):133-149.
PMID: 38767023
Objective: The aim of our study is to better understand the genetic architecture and pathological mechanisms underlying neurodegeneration in idiopathic Parkinson's disease (iPD). We hypothesized that a fraction of iPD...
2.
Payne T, Burgess T, Bradley S, Roscoe S, Sassani M, Dunning M, et al.
Brain
. 2023 Dec;
147(1):267-280.
PMID: 38059801
The heterogenous aetiology of Parkinson's disease is increasingly recognized; both mitochondrial and lysosomal dysfunction have been implicated. Powerful, clinically applicable tools are required to enable mechanistic stratification for future precision...
3.
Capriglia F, Burgess T, Bandmann O, Mortiboys H
J Parkinsons Dis
. 2023 Sep;
13(6):851-864.
PMID: 37694310
No abstract available.
4.
Mihaylov S, Castelli L, Lin Y, Gul A, Soni N, Hastings C, et al.
Nat Commun
. 2023 Sep;
14(1):5496.
PMID: 37679383
PGC-1α plays a central role in maintaining mitochondrial and energy metabolism homeostasis, linking external stimuli to transcriptional co-activation of genes involved in adaptive and age-related pathways. The carboxyl-terminus encodes a...
5.
Wason J, Bandmann O
Nat Rev Drug Discov
. 2023 Aug;
22(9):681-682.
PMID: 37537382
No abstract available.
6.
Payne T, Appleby M, Buckley E, van Gelder L, Mullish B, Sassani M, et al.
Mov Disord
. 2023 May;
38(8):1493-1502.
PMID: 37246815
Background: Rescue of mitochondrial function is a promising neuroprotective strategy for Parkinson's disease (PD). Ursodeoxycholic acid (UDCA) has shown considerable promise as a mitochondrial rescue agent across a range of...
7.
Keatinge M, Gegg M, Watson L, Mortiboys H, Li N, Dunning M, et al.
Dis Model Mech
. 2023 Mar;
16(6).
PMID: 36951087
Heterozygous variants in GBA1, encoding glucocerebrosidase (GCase), are the most common genetic risk factor for Parkinson's disease (PD). Moreover, sporadic PD patients also have a substantial reduction of GCase activity....
8.
Foltynie T, Gandhi S, Gonzalez-Robles C, Zeissler M, Mills G, Barker R, et al.
Brain
. 2023 Mar;
146(7):2717-2722.
PMID: 36856727
An increase in the efficiency of clinical trial conduct has been successfully demonstrated in the oncology field, by the use of multi-arm, multi-stage trials allowing the evaluation of multiple therapeutic...
9.
Luxenburger A, Clemmens H, Hastings C, Harris L, Ure E, Cameron S, et al.
Biomolecules
. 2023 Jan;
13(1).
PMID: 36671460
Parkinson's Disease is the most common neurodegenerative movement disorder globally, with prevalence increasing. There is an urgent need for new therapeutics which are disease-modifying rather than symptomatic. Mitochondrial dysfunction is...
10.
Shribman S, Burrows M, Convery R, Bocchetta M, Sudre C, Acosta-Cabronero J, et al.
Mov Disord
. 2022 Jun;
37(8):1728-1738.
PMID: 35723521
Background: Cognitive impairment is common in neurological presentations of Wilson's disease (WD). Various domains can be affected, and subclinical deficits have been reported in patients with hepatic presentations. Associations with...